Objective: To measure the comprehensive geriatric assessment (CGA) in elder non-Hodgkin's Lymphoma (NHL) patients in a cross-sectional study; to compare the differences between Eastern Cooperative Oncology Group (ECOG)-performance status (PS) and CGA. Methods: CGA stratification included the following 3 instrument assessments: activity of daily living (ADL);instrumental activity of daily living (IADL);comorbidity score according to the modified cumulative illness rating score for geriatrics (MCIRS-G). According to CGA and age, NHL patients, aged ≥60 years, were classified as"fit","unfit"and"frail"groups. ECOG-PS was evaluated and compared with CGA. Results: According to CGA, 51.6% senior NHL patients (33 cases) were classified as"fit", 12.5%(8 cases) as"unfit"and 35.9%(23 cases) as"frail". Several comorbidities were observed in majority patients, such as cardiovascular disease, diabetes mellitus and hypertension. In the"younger aged"patients between 60 to 64ys, 25%(3/12) was considered as"frail". However, this proportion increased to 42.9%(6/14) in patients older than 80ys. Moreover, impaired CGA was observed in 38.9%(21/54) of ECOG-PS ≤1 patient. Conclusions: Impaired CGA is as common as approximately half in elderly NHL patients and more than one third even in ECOG-PS ≤1 patients. ECOG-PS may underestimate the impaired fitness function in elder NHL patients.
目的： 提供老年非霍奇金淋巴瘤（NHL）患者老年综合评估（CGA）评分的分布数据；对比美国东部肿瘤协作组（ECOG）体力状况评分与CGA评分的差异。 方法： 将北京医院血液科2014年2月至2017年2月收治的≥60岁NHL患者进行CGA评分，包括日常生活活动功能评定量表（ADL）、工具性日常生活活动功能评估量表（IADL）和改良老年疾病累计评分表（MCIRS-G），依据量表得分及年龄将患者分为适合组、不适合组和脆弱组。采用横断面研究，了解其临床特征，分析CGA评分分布，并对比ECOG体力状况评分与CGA评分的差异。 结果： 64例老年NHL患者纳入研究。根据CGA评估，适合组占51.6%（33例），不适合组占12.5%（8例），脆弱组占35.9%（23例）；大多数患者有合并症，其中心血管疾病、糖尿病、高血压病较为常见；在60~64岁较年轻的患者中仍有25%（3/12）的患者CGA评估为"脆弱"，在≥80岁的高龄患者中"脆弱"比例达42.9%（6/14）；ECOG体力状况评分≤1分的患者中仍有38.9%（21/54）存在CGA受损。 结论： 依据CGA评估，60岁及以上NHL患者中近一半存在CGA受损；在ECOG体力状况评分≤1分的患者中仍有部分患者存在CGA受损，提示ECOG评分会低估老年NHL患者功能受损程度。.
Keywords: Aged; Comprehensive geriatric assessment; Eastern Cooperative Oncology Group (ECOG)-performance status; Lymphoma, non-Hodgkin.